May 11, 2020 / 12:49 PM / 21 days ago

BRIEF-Aileron Therapeutics Reports First Quarter 2020 Financial Results And Provides Corporate Update

May 11 (Reuters) - Aileron Therapeutics Inc:

* AILERON THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

* AILERON THERAPEUTICS - ENROLLMENT COMPLETED IN DOSE OPTIMIZATION PART OF ONGOING PHASE 1B/2 CLINICAL TRIAL OF ALRN-6924

* AILERON THERAPEUTICS - SCHEDULED TO REPORT INTERIM RESULTS FROM DOSE OPTIMIZATION PART OF PHASE 1B/2 TRIAL IN Q2 2020

* AILERON THERAPEUTICS - PLANNING FINAL DATA READOUT IN Q4 2020 FROM DOSE OPTIMIZATION PART OF PHASE 1B/2 TRIAL

* AILERON THERAPEUTICS - IMPLEMENTED MEASURES TO REDUCE OPERATING EXPENSES TO EXTEND ITS CASH RUNWAY TO Q1 2021

* AILERON THERAPEUTICS - DETERMINED TO FOCUS ITS EFFORTS ON DEVELOPMENT OF ALRN-6924 AS CHEMOPROTECTIVE AGENT

* AILERON THERAPEUTICS - DOES NOT PLAN TO ADVANCE DEVELOPMENT OF ALRN-6924 FOR ANY OTHER PROGRAM AT THIS TIME

* AILERON THERAPEUTICS - MONITORING EFFECT OF CORONAVIRUS PANDEMIC, WHICH MAY IMPACT TIMING OF CO’S PLANNED DATA ANNOUNCEMENTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below